WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Ver el documento en el formato PDF
Índice de contenido
Ver el documentoPreface
Ver el documentoIntroduction
Abrir esta carpeta y ver su contenidoParasitic infections
Abrir esta carpeta y ver su contenidoInsect and arachnid bites and stings
Abrir esta carpeta y ver su contenidoSuperficial fungal infections
Abrir esta carpeta y ver su contenidoSubcutaneous fungal infections
Abrir esta carpeta y ver su contenidoBacterial infections
Abrir esta carpeta y ver su contenidoViral infections
Abrir esta carpeta y ver su contenidoEczematous diseases
Abrir esta carpeta y ver su contenidoScaling diseases
Abrir esta carpeta y ver su contenidoPapulosquamous diseases
Ver el documentoCutaneous reactions to drugs
Abrir esta carpeta y ver su contenidoPigmentary disorders
Cerrar esta carpetaPremalignant lesions and malignant tumours
Ver el documentoActinic keratosis
Ver el documentoBasal cell and squamous cell carcinomas
Ver el documentoMalignant melanoma
Abrir esta carpeta y ver su contenidoPhotodermatoses
Abrir esta carpeta y ver su contenidoBullous dermatoses
Ver el documentoAlopecia areata
Ver el documentoUrticaria
Abrir esta carpeta y ver su contenidoConditions common in children
Ver el documentoAcne vulgaris
Ver el documentoPruritus
Ver el documentoTropical ulcers
Abrir esta carpeta y ver su contenidoAntimicrobial drugs
Abrir esta carpeta y ver su contenidoAntifugal drugs
Abrir esta carpeta y ver su contenidoAntiseptic agents
Abrir esta carpeta y ver su contenidoKeratoplastic and keratolytic agents
Abrir esta carpeta y ver su contenidoScabicides and pediculicides
Abrir esta carpeta y ver su contenidoAnti-inflammatory and antipruritic drugs1
Abrir esta carpeta y ver su contenidoAntiallergics and drugs used in anaphylaxis
Abrir esta carpeta y ver su contenidoUltraviolet radiation-blocking agents (sunscreens)
Abrir esta carpeta y ver su contenidoMiscellaneous drugs
Abrir esta carpeta y ver su contenidoAnnex
Ver el documentoSelected WHO Publications of Related Interest
Ver el documentoBack cover
 

Malignant melanoma

Malignant melanoma resulting from malignant changes in cutaneous melanocytes is the most fatal form of skin cancer. None the less, with proper early diagnosis and adequate excision of the lesions, most melanomas can be treated without long-term consequences. Most melanomas develop from the normal melanocyte population of the skin, but 30-40% may arise from pre-existing moles. Signs that malignant changes may be occurring (although not predictive in themselves) include a rapid change in size, a change in colour (with or without spread of pigment to the adjacent skin), inflammation of the surrounding skin, and bleeding or ulceration of a pigmented lesion. Early lesions may be flat and look like an unusual freckle. The colour is not uniform with areas of dark coloration contrasting with light areas. This variation in colour is a particularly important sign.

Treatment

Suspicious lesions that are small in size (e.g. diameter ≤ 6 mm) should be excised with a border of 3-4 mm initially. If the lesions are too large to excise, biopsies should be taken for histological examination. The depth of the lesion should be determined, if possible, as this is important in deciding whether additional surgery is required and is also essential for prognosis. Re-excision of margins of normal skin between 1 and 2 cm in width around the original tumour may be done, depending on the depth of invasion found on histological examination. The depth of invasion in the skin is also an important factor in determining the potential for the lesion to metastasize to distant sites.

 

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 24 abril 2012